# Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

> **NCT05427812** · PHASE1,PHASE2 · TERMINATED · sponsor: **Ichnos Sciences SA** · enrollment: 29 (actual)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **DRUG:** ISB 1442 SC injection escalating doses
- **DRUG:** ISB 1442 SC injection at RP2D

## Key facts

- **NCT ID:** NCT05427812
- **Lead sponsor:** Ichnos Sciences SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-09-27
- **Primary completion:** 2024-11-19
- **Final completion:** 2024-11-19
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05427812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05427812, "Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05427812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*